DOI 10.1016/j.lungcan.2026.109487
Comparative performance of shape-sensing robotic-assisted bronchoscopy and CT-guided transthoracic biopsy in diagnosing peripheral pulmonary lesions.
Аннотация
BACKGROUND
Lung cancer is the leading cause of cancer mortality. Nonsurgical biopsies are obtained by computed tomography-guided transthoracic biopsy (CTTB) or bronchoscopically. Due to previous limitations in conventional flexible bronchoscopic techniques, the development of robotic-assisted bronchoscopy (RAB) platforms have emerged. We aim to compare the outcomes of shape-sensing RAB (ssRAB) and CTTB using a strict diagnostic yield (DY) definition.
STUDY DESIGN AND
METHODS
This is a single center observational study. Data was collected from adults (age ≥ 18) who underwent a lung biopsy with CTTB or ssRAB between March 21, 2023 and August 31, 2024. The primary outcome was DY. The secondary outcomes were molecular adequacy, time to treatment for new non-small cell lung cancer (NSCLC) diagnoses, procedure complications, and procedure duration.
RESULTS
A total of 638 patients (ssRAB N = 489, CTTB N = 149) were included. DY for ssRAB was 84.3 % vs 80.5 % in CTTB (p = 0.347). Compared to CTTB, the ssRAB group had a lower incidence of pneumothorax (PTX) (1.4 % vs 29.5 %, p < 0.001), PTX requiring a chest tube placement (1.4 % vs 4.7 %, p = 0.039), and pulmonary hemorrhage (0.2 % vs 14.1 %, p < 0.001). Molecular adequacy was 89.6 % in ssRAB vs. 79.1 % CTTB (p = 0.022). Adjusted analysis found a similar DY between ssRAB and CTTB [adjusted OR (95 % CI): 1.14 (0.82; 1.60)] but increased molecular adequacy for ssRAB vs CTTB [adjusted OR (95 % CI): 2.21 (1.18; 4.16)], and lower incidence of PTX for ssRAB vs CTTB [adjusted OR (95 % CI): 0.04 (0.01; 0.08)]. Time from biopsy to treatment initiation for new NSCLC diagnoses was faster with ssRAB compared to CTTB [adjusted mean difference (95 % CI): -22.276 (-29.983--14.547) days]; however, a longer procedure time (adjusted mean difference (95 % CI): 10.572 [8.653; 12.491] minutes).
INTERPRETATION: These findings suggest ssRAB may have a comparable diagnostic yield to CTTB but potentially provide superior quantity sufficient biopsies for molecular analysis at a lower complication rate. Adjusting for confounding variables, ssRAB may have fewer complication rates, superior molecular adequacy, and fewer days from biopsy to treatment initiation for new NSCLC diagnoses.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.